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ASPERGILLOSIS
Aspergillosis disseminating to the central nervous system
(CNS) is amongst the most fearsome manifestations of
opportunistic fungal infections.1 Among the various
disease causing subtypes in the genus Aspergillus, A.
fumigatus is the most commonly identified human
pathogen most ly af fect ing immunocompromised
individuals. The incidence appears to be rising due to
better means of diagnosis, better reporting and increase
in immunocompromised patient population. The disease
was once considered to be restr icted to
immunocompromised patients; however a recent increase
has been observed in the immunocompetent population
as well, especially in Pakistan and India, where more than
half of all the affected patients did not have any evidence
of immunosuppression, a population known as the
“apparently immunocompetent”.1-9 Primary sites of
aspergillus infection are the lungs in immunosuppressed
and paranasal sinuses in immunocompetent individuals.
CNS may also be involved as a primary site, but more
commonly it is involved secondary to hematogenous
spread from disease elsewhere or as a result of
contiguous extension from adjacent structures.3,4 The
CNS is now the second commonest organ to be
secondarily affected by invasive aspergillosis. Intracranial
aspergillosis has been classified as extradural, intradural
or a combination of both. Extradural disease is associated
with the best outcome.4
The mechanism of damage at the cellular level in cerebral
Aspergillus lesions has been shown to be due to secretion
of various necrotizing factors with activity toward neurons
and glial cells.10 Aspergillus also has a tendency to
invade blood vessels producing a necrotizing angiitis
leading to secondary thrombosis with or without
hemorrhage.11 Aspergillomas, reactive masses formed
commonly in immunocompetent patients, are mainly
present in the frontal or temporal lobes and rarely, in the
posterior fossa as well.12 Out of more than 40 cases
managed at our institution over the past ten years, we
have come across just two patients with aspergillomas
involving the cerebellum. Aspergillomas may also co-exist
with septic or vascular infarcts or with intracranial
abscesses.
In our country where solid organ transplant and acquired
immunodeficiency syndrome are not that common, the
majority of immunocompromised patients are due to
diabetes mellitus.4 In nearly half of the patients suffering
from aspergi l losis, however, we did not f ind any
predisposing underlying condition. 
Multiple studies have described a variety of presenting
features such as nasal stuffiness, headache, peri-orbital
pain, vomiting, seizures, hemi paresis, cranial nerve
palsies, impaired consciousness.5,3,14 In patients with
orbital involvement, proptosis, ophthalmoplegia and visual
deterioration are usually the presenting features.13-15
Patients with aspergillomas may also present with
classical skull-base syndromes such as the orbital apex
syndrome, cavernous sinus syndrome, polyneuritis
cranialis and orbito-cranial syndromes, depending upon
the site of lesion. In one study of patients suffering from
CNS aspergillosis, 64 patients out of 89 presented with
skull base syndromes.16 The disease is usually slowly
progressive and symptoms may persist for months before
clinically apparent. 
Craniocerebral aspergillosis is difficult to diagnose, as
blood cultures and cerebrospinal fluid (CSF) cultures are
frequently negative.17 Other serologic tests such as
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double diffusion counter immuno-electrophoresis,
immuno- fluorescence, or enzyme-linked immuno-sorbent
assay (ELISA) may be helpful in arriving at a diagnosis but
are rarely performed.17,18 CSF analysis findings are
usually non-specific for fungal disease, cell counts are
usually elevated, showing pleocytosis, proteins also are
usually elevated and glucose may be decreased. Antibody
detection in serum or CSF is also not shown to be useful.
The yield of PCR is comparatively high in cases of
disseminated invasive aspergi l losis and cerebral
abscesses, but not in patients with aspergillomas. We do
not recommend the use of CSF in the diagnosis of
cerebral aspergillosis as obtaining a CSF sample through
lumbar puncture in such a patient may be dangerous.18
A peri-operative squash smear or frozen section seems to
us a much better means of identifying the pathology and
we strongly recommend that it be carried out in all
patients with suspected aspergillus infection.18
Cerebral aspergil losis presents with four principal
neuroimaging f indings. These include infarct ion,
abscesses, infiltration originating from paranasal sinuses
or orbits, and intracranial (intra or extra-axial) space
occupying lesions. All of these may also co-exist in the
same patient.18,19 On CT scanning the lesions are
characteristically hyper-dense with mass effect and may
or may not show contrast enhancement.18 Calcifications
within the fungal mass may also be present. On MR
imaging, the classical description is that of an irregular
space occupying mass lesion having hypointense to
isointense signals on T1 weighted images due to
coagulative necrosis of brain tissue secondary to fungal
involvement of vessels, a f inding that has been
histological ly proven.20 On T2 weighted images,
hypointense signals when present are considered
characteristic of aspergillus lesions. However, slightly less
hypointense zones may also be present within the wall of
these lesions. These have been attributed to the dense
population of aspergillus hyphal elements or recent
hemorrhage, and are not considered characteristic.21,22
Presence of iron, manganese, and magnesium in the
fungal concretions may also lead to hypointense signals
on T2 weighted images.21-23 On contrast administration,
the lesion may show either br ight homogenous
enhancement, ring enhancement or no enhancement,
although a thick perimeter of enhancement is the most
characteristic feature of aspergillomas, especially in the
presence of a competent host defense mechanism. 
The cornerstone of management of intracranial
aspergilloma remains surgical excision, a standard based
on reports, personal experiences and on the basis of a
recent multifactorial risk analysis.18,24,25 Surgical
excision must always be followed by aggressive antifungal
chemotherapy to achieve best response.26-29 Radical
surgery done early and as a first procedure has been
considered superior to repeated sub radical resections
but it has also been suggested that radical excision of
fungal mass does not seem to be necessary.4,30 The risk
of morbidity seem excessive for an infective process and
therefore, sub radical excision aimed at establishing
diagnosis and reducing disease burden followed by
systemic antifungal therapy seems to be a better course
of action. However, when a lesion in a non-eloquent area
is encountered that can be safely and totally excised, the
best plan would be to eradicate the lesion completely.
Sub-radical resection may be reserved for lesions which
are only partially resectable. In a lesion occupying an
eloquent area a biopsy would suffice.
Whenever the nasal passages are suspected to be
involved, a thorough debridement of nasal passages
should be simultaneously carr ied out by
otorhinolaryngologists.18 When the globe is involved the
patient mostly does not have vision in that eye and
enucleation should be considered. 
Per i-operat ive management of these pat ients is
challenging. The aspergillus at times shows a peculiar
response to surgery and seems to f lare up post-
operatively assuming a rapidly fulminant course if not
dealt with aggressively. The response is characterized by
high grade fever, tachycardia and malignant cerebral
edema refractory to medical management, presumed to
be due to iatrogenic acute aspergi l lus meningo-
encephalitis. Whenever such a response is encountered,
patient should be managed on principles of malignant
cerebral swell ing with consideration for mannitol,
steroids, decompressive craniotomy, and i f  ever
necessary, decompressive lobectomies, along with other
aspects of neuro-intensive care such as intracranial
pressure monitoring and propofol sedation. Based on
anecdotal experience, it is suggested that pre-operative
use of itraconazole may be associated with better
outcome.31 Special attention should also be given to
patient's metabolic profile, as the patient is under the
influence of a number of factors which may lead to
metabolic derangements. Such caution is not required in
patients have extradural disease alone. It is only when
the fungus involves brain parenchyma, and during surgery
the dura is breeched that we see series of events referred
to as “forest fire phenomenon”.18
Until recently, cerebral aspergillosis was treated routinely
with intravenous amphoter ic in B combined with
flucytosine or itraconazole.4,27-29,32 But with the
introduction of itraconazole, the paradigm has shifted as
many multicenter clinical trials have proven its efficacy
over the previous drug regimens.4,27-29,32 In addition to
efficacy, other advantages of itraconazole therapy are
that it is less toxic and thus better tolerated although it
shows variable and inconsistent absorption in some
patients. Two newer parenteral antifungal medications
(echinocandins) caspofungin and micafungin are also
under scrutiny and a newer triazole, voriconazole, is also
becoming increasingly popular.33-35 Several studies
suggest voriconazole is more effective and less toxic than
amphotericin B, and has been proposed as the first line
treatment of aspergillosis.33-35 There is also the debate
over monotherapy and combination therapy and animal
models have suggested that combination of liposomal
amphotericin B and voriconazole given concurrently are
significantly efficacious in comparison with any other
combination, even when administered in sub-optimal
doses.33,34 There may also be some advantage in the
administration of granulocye monocyte colony stimulating
factors (GMCSF) and  recombinant-IFN, although
evidence is lacking.36,37
Unlike intracranial tuberculomas and intracranial hydatid
cysts, intracranial aspergillomas do not carry the same
favourable prognosis and initial literature suggested a
mortality of nearly 100 %.38 Beside the adverse effects
of antifungal medications, some specific complications
reported for these patients include vascular invasion
leading to infarcts, intracerebral hemorrhage, fungal
disseminat ion, massive anaphylaxis, meningit is,
formation of mycot ic aneurysm, subarachnoid
hemorrhage and hydrocephalus. Patients who are
immunocompetent or who have only extradural disease
have the best outcomes, with reported mortality rates
ranging from 40-80%. The mortality rate is reduced to
less than 20% if the disease is entirely extradural.3,4,18
Patients with underlying malignancies or who have
intraparenchymal disease have the worst outcomes.38
Presence of vascular invasion nearly always indicates a
poor prognosis.
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